We studied a subset of hematopoietic stem cells (HSCs) that are defined by elevated expression of CD41 (CD41hi) and showed bias for differentiation toward megakaryocytes (Mks). Mouse models of myeloproliferative neoplasms (MPNs) expressing JAK2-V617F (VF) displayed increased frequencies and percentages of the CD41hi vs CD41lo HSCs compared with wild-type controls. An increase in CD41hi HSCs that correlated with JAK2-V617F mutant allele burden was also found in bone marrow from patients with MPN. CD41hi HSCs produced a higher number of Mk-colonies of HSCs in single-cell cultures in vitro, but showed reduced long-term reconstitution potential compared with CD41lo HSCs in competitive transplantations in vivo. RNA expression profiling showed an upregulated cell cycle, Myc, and oxidative phosphorylation gene signatures in CD41hi HSCs, whereas CD41lo HSCs showed higher gene expression of interferon and the JAK/STAT and TNFα/NFκB signaling pathways. Higher cell cycle activity and elevated levels of reactive oxygen species were confirmed in CD41hi HSCs by flow cytometry. Expression of Epcr, a marker for quiescent HSCs inversely correlated with expression of CD41 in mice, but did not show such reciprocal expression pattern in patients with MPN. Treatment with interferon-α further increased the frequency and percentage of CD41hi HSCs and reduced the number of JAK2-V617F+ HSCs in mice and patients with MPN. The shift toward the CD41hi subset of HSCs by interferon-α provides a possible mechanism of how interferon-α preferentially targets the JAK2 mutant clone.

Department of Biology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Biomedicine Experimental Hematology University Hospital Basel University of Basel Basel Switzerland

Department of Biosystems Science and Engineering Eidgenössische Technische Hochschule Zurich Basel Switzerland

Department of Hematology Oncology Hemostaseology and Stem Cell Transplantation Faculty of Medicine Rheinisch Westfälische Technische Hochschul Aachen University Aachen Germany

Institute of Medical Genetics and Pathology University Hospital Basel Basel Switzerland; and

Internal Medicine 5 Department of Hematology and Oncology Medical University Innsbruck Innsbruck Austria

Swiss Institute of Bioinformatics Basel Switzerland

Blood. 2021 Apr 22;137(16):2129-2130. doi: 10.1182/blood.2021011273. PubMed

Zobrazit více v PubMed

Yamamoto R, Morita Y, Ooehara J, et al. . Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell. 2013;154(5):1112-1126. PubMed

Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. . Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232-236. PubMed

Gekas C, Graf T. CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. Blood. 2013;121(22):4463-4472. PubMed

Haas S, Hansson J, Klimmeck D, et al. . Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors. Cell Stem Cell. 2015;17(4):422-434. PubMed

Nishikii H, Kanazawa Y, Umemoto T, et al. . Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes. Stem Cells. 2015;33(7):2196-2207. PubMed PMC

Rodriguez-Fraticelli AE, Wolock SL, Weinreb CS, et al. . Clonal analysis of lineage fate in native haematopoiesis. Nature. 2018;553(7687):212-216. PubMed PMC

Shin JY, Hu W, Naramura M, Park CY. High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. J Exp Med. 2014;211(2):217-231. PubMed PMC

Grinenko T, Arndt K, Portz M, et al. . Clonal expansion capacity defines two consecutive developmental stages of long-term hematopoietic stem cells. J Exp Med. 2014;211(2):209-215. PubMed PMC

Kent DG, Copley MR, Benz C, et al. . Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood. 2009;113(25):6342-6350. PubMed

Gur-Cohen S, Itkin T, Chakrabarty S, et al. . PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells [published correction appears in Nat Med. 2016 Apr;22(4):446]. Nat Med. 2015;21(11):1307-1317. PubMed PMC

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-679. PubMed

Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. PubMed

Bellosillo B, Martínez-Avilés L, Gimeno E, et al. . A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia. 2007;21(6):1331-1332. PubMed

Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008;111(7):3863-3866. PubMed

Lundberg P, Takizawa H, Kubovcakova L, et al. . Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014;211(11):2213-2230. PubMed PMC

Kiladjian JJ. Long-term treatment with interferon alfa for myeloproliferative neoplasms. Lancet Haematol. 2017;4(4):e150-e151. PubMed

Essers MA, Offner S, Blanco-Bose WE, et al. . IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908. PubMed

Tiedt R, Hao-Shen H, Sobas MA, et al. . Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940. PubMed

Hasan S, Lacout C, Marty C, et al. . JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood. 2013;122(8):1464-1477. PubMed

Grisouard J, Li S, Kubovcakova L, et al. . JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128(6):839-851. PubMed

Schaefer BC, Schaefer ML, Kappler JW, Marrack P, Kedl RM. Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. Cell Immunol. 2001;214(2):110-122. PubMed

Müller U, Steinhoff U, Reis LF, et al. . Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918-1921. PubMed

Mansier O, Kilani B, Guitart AV, et al. . Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. Blood. 2019;134(26):2383-2387. PubMed

Rodgers JT, King KY, Brett JO, et al. . mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature. 2014;510(7505):393-396. PubMed PMC

Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature. 2010;465(7299):793-797. PubMed PMC

Pietras EM, Lakshminarasimhan R, Techner JM, et al. . Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med. 2014;211(2):245-262. PubMed PMC

Mullally A, Bruedigam C, Poveromo L, et al. . Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692-3702. PubMed PMC

Dumont FJ, Coker LZ. Interferon-alpha/beta enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur J Immunol. 1986;16(7):735-740. PubMed

Yokota T, Oritani K, Butz S, et al. . The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. Blood. 2009;113(13):2914-2923. PubMed PMC

Ooi AG, Karsunky H, Majeti R, et al. . The adhesion molecule esam1 is a novel hematopoietic stem cell marker. Stem Cells. 2009;27(3):653-661. PubMed PMC

Zheng L, Li MP, Gou ZP, et al. . A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. Br J Clin Pharmacol. 2015;79(4):650-659. PubMed PMC

Nakamura-Ishizu A, Matsumura T, Stumpf PS, et al. . Thrombopoietin Metabolically Primes Hematopoietic Stem Cells to Megakaryocyte-Lineage Differentiation. Cell Rep. 2018;25(7):1772-1785 e1776. PubMed

Rao TN, Hansen N, Hilfiker J, et al. . JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative ne oplasms. Blood. 2019;134(21):1832-1846. PubMed PMC

Baumeister J, Chatain N, Hubrich A, et al. . Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2020;34(4):1062-1074. PubMed

Roch A, Trachsel V, Lutolf MP. Brief Report: Single-Cell Analysis Reveals Cell Division-Independent Emergence of Megakaryocytes From Phenotypic Hematopoietic Stem Cells. Stem Cells. 2015;33(10):3152-3157. PubMed

Walter D, Lier A, Geiselhart A, et al. . Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature. 2015;520(7548):549-552. PubMed

Austin RJ, Straube J, Bruedigam C, et al. . Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2020;34(4):1075-1089. PubMed PMC

Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 1999;397(6721):710-713. PubMed

Prendergast AM, Kuck A, van Essen M, Haas S, Blaszkiewicz S, Essers MA. IFNα-mediated remodeling of endothelial cells in the bone marrow niche. Haematologica. 2017;102(3):445-453. PubMed PMC

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms